The Yale Cancer Center (YCC) was designated as an NCI Comprehensive Cancer Center in 1974. YCC has elected to profoundly alter its structure to better facilitate clinical translation of its abundant scientific strengths. A particularly important component, taken in consultation with the NCI, was relocation of operational control of Medical Oncology to YCC, to augment Center influence over the Clinical Trials Program. An administrative 3-year extension from the NCI enabled these changes. The new Director, Richard Edelson, an accomplished translational scientist, has led the Center since these pivotal changes were initiated in 2003. Over $68 million of institutional support permitted YCC to enhance facilities and recruit 60 external faculty members, including leaders of 5 of the 8 Research Programs, 6 of the 11 interdisciplinary cancer disease site teams and both the Clinical Research Services Core and Protocol Review Committee. Strategic scientific recruitments include Joseph Schlesinger (pioneer in the design of inhibitors of receptor tyrosine kinases and now Co-Leader of the Signal Transduction Program) and Jeffrey Sklar (a leading innovator in molecular diagnosis of cancer and now Co-Leader of the Gene Regulation and Functional Genomics Program). Preserving continuity by reappointing the Deputy Director, the Director appointed new Associate Directors of Basic and Clinical Sciences. All Research Programs now thematically stress mechanistic themes, and the Clinical Division has been organized around the three main cancer treatment modalities (small molecules/anticancer agents, radiation therapy, and biological/ immunological agents), rather than being confined to single disease sites. Due to these collective YCC structural and functional changes, the number of investigator initiated clinical trials, based on YCC science, have dramatically increased. Construction has begun on a $460M new Clinical Cancer Tower, proximal to the YCC scientific laboratories. The 210 YCC members come from 27 Yale Departments and 4 Schools. Since the last CCSG submission, total peer-reviewed, annual direct costs of cancer-relevant research support increased by 42%, from $43 million to $62 million, inclusive of $15.3 million from the NCI. Integration of the new scientific and clinical investigators has permitted the YCC to target 8 sets of grouped research projects for focused development. Last approved in 1998, YCC continues to satisfy guidelines for Comprehensiveness. Based on the NCI total cost funding base of $25.6 million, YCC is requesting a budget of $3.8 million in total costs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016359-33S2
Application #
8306376
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-07-01
Project End
2013-07-31
Budget Start
2011-08-03
Budget End
2013-07-31
Support Year
33
Fiscal Year
2011
Total Cost
$10,000
Indirect Cost
Name
Yale University
Department
Dermatology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287

Showing the most recent 10 out of 675 publications